Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.46 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.46 |
| ▸ | P2RX3 | P56373 | 10/20 | 0.43 |
| ▸ | P2RX2 | Q9UBL9 | 10/20 | 0.43 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.39 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.39 |
| ▸ | DHFR | P00374 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30151419 | 1.00 | KDM4E (0.52) | KDM4EALDH1A1SMN1; SMN2CSNK1A1CLK4 | |
| SCHEMBL25320586 | 0.86 | CSNK1A1 (0.42) | KDM4EALDH1A1SMN1; SMN2CSNK1A1CLK4 | |
| SCHEMBL30068026 | 0.80 | TLR8 (0.45) | KDM4EALDH1A1SMN1; SMN2CSNK1A1CLK4 | |
| SCHEMBL25323208 | 0.80 | TLR8 (0.45) | KDM4EALDH1A1SMN1; SMN2CSNK1A1CLK4 | |
| Hydrazine SCHEMBL27895468 | 0.79 | ALDH1A1 (0.52) | KDM4EALDH1A1SMN1; SMN2CSNK1A1CLK4 | |
| SCHEMBL26627840 | 0.79 | TLR8 (0.44) | KDM4EALDH1A1SMN1; SMN2CSNK1A1CLK4 | |
| SCHEMBL3417149 | 0.78 | P2RX3 (0.60) | ALDH1A1P2RX3P2RX2DHFR | |
| SCHEMBL29556850 | 0.78 | ALDH1A1 (0.55) | KDM4EALDH1A1SMN1; SMN2PIN1 | |
| SCHEMBL145005 | 0.78 | ALDH1A1 (0.55) | KDM4EALDH1A1SMN1; SMN2PIN1 | |
| SCHEMBL121368 | 0.77 | ALDH1A1 (0.53) | KDM4EALDH1A1SMN1; SMN2PIN1DHFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 169 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118994194-A | Small molecular compound with IDO1 inhibitory activity and preparation method and application thereof | 新疆医科大学第一附属医院 | 2024-11-22 | — | — | CN | claimed |
| WO-2023245611-A1 | SMALL MOLECULE COMPOUND WITH TTK INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR, AND USE THEREOF | 四川大学华西医院 | 2023-12-28 | — | — | WO | claimed |
| CN-106243045-A | A kind of preparation method of 2,5 dimethoxy 4 aminopyrimidines | 常州大学 | 2016-12-21 | — | — | CN | claimed |
| EP-4741387-A1 | CRYSTAL FORM OF BIPYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | Jiangsu Yahong Meditech Co., Ltd. (CN) | 2026-05-13 | — | — | EP | disclosed |
| EP-4741386-A1 | PYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | Jiangsu Yahong Meditech Co., Ltd. (CN) | 2026-05-13 | — | — | EP | disclosed |
| US-20260108527-A1 | POLO LIKE KINASE 4 INHIBITORS | ORIC PHARMACEUTICALS INC (US) | 2026-04-23 | — | — | US | disclosed |
| EP-4673449-A1 | CYCLIN DEPENDENT KINASE DEGRADERS AND METHODS OF USE THEREOF | Differentiated Therapeutics Inc (US) | 2026-01-07 | — | — | EP | disclosed |
| US-12459922-B2 | PARP7 inhibitors | GILEAD SCIENCES, INC. (US) | 2025-11-04 | — | — | US | disclosed |
| US-20250289799-A1 | PYRIMIDINE COMPOUND, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL USE THEREOF | JIANGSU YAHONG MEDITECH CO., LTD. (CN) | 2025-09-18 | — | — | US | disclosed |
| EP-4598912-A1 | POLO LIKE KINASE 4 INHIBITORS | Oric Pharmaceuticals, Inc. (US) | 2025-08-13 | — | — | EP | disclosed |
| US-12312339-B2 | Polo like kinase 4 inhibitors | ORIC PHARMACEUTICALS, INC. (US) | 2025-05-27 | — | — | US | disclosed |
| WO-2010046388-A1 | SUBSTITUTED (AZA) -1-METHYL-1H-QUINOLIN-2-ONES AS ANTIBACTERIALS | GLAXO GROUP LIMITED (GB) | 2010-04-29 | — | — | WO | disclosed |
| WO-2009150240-A1 | IMIDAZOPYRIDINE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES | ASTEX THERAPEUTICS LIMITED (GB) | 2009-12-17 | — | — | WO | disclosed |
| WO-2009150240-A1 | IMIDAZOPYRIDINE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES | ASTEX THERAPEUTICS LIMITED (GB) | 2009-12-17 | — | — | WO | disclosed |
| US-20090253687-A1 | Fused Heterocyclic Compounds and Their Use as Mineralocorticoid Receptor Ligands | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-08 | — | — | US | disclosed |
| EP-1971596-A2 | FUSED HETEROCYCLIC COMPOUNDS AND THEIR USE AS MINERALOCORTICOID RECEPTOR LIGANDS | Takeda Pharmaceutical Company Limited (JP) | 2008-09-24 | — | — | EP | disclosed |
| WO-2007077961-A2 | FUSED HETEROCYCLIC COMPOUNDS AND THEIR USE AS MINERALOCORTICOID RECEPTOR LIGANDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-07-12 | — | — | WO | disclosed |
| US-20060189613-A1 | Sulphonamide Compounds that Modulate Chemokine Receptor Activity (CCR4) | ASTRAZENECA AB (SE) | 2006-08-24 | — | — | US | disclosed |
| EP-1633723-A1 | SULPHONAMIDE COMPOUNDS THAT MODULATE CHEMOKINE RECEPTOR ACTIVITY (CCR4) | AstraZeneca AB (SE) | 2006-03-15 | — | — | EP | disclosed |
| WO-2004108690-A1 | SULPHONAMIDE COMPOUNDS THAT MODULATE CHEMOKINE RECEPTOR ACTIVITY (CCR4) | ASTRAZENECA AB (SE) | 2004-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260108527-A1 | POLO LIKE KINASE 4 INHIBITORS | PLK4, PLK2, PLK3 | KDM4E 1527/4885ALDH1A1 2205/4885SMN1; SMN2 3896/4885 |
| US-20060189613-A1 | Sulphonamide Compounds that Modulate Chemokine Receptor Activity (CCR4) | CCR4, CCR5, CCR2 | KDM4E 1883/4885ALDH1A1 2306/4885SMN1; SMN2 3553/4885 |
| US-12312339-B2 | Polo like kinase 4 inhibitors | PLK4, PLK2, PLK3 | KDM4E 858/4885ALDH1A1 2211/4885SMN1; SMN2 2786/4885 |
| US-12459922-B2 | PARP7 inhibitors | PARP1, PARP11, PARP2 | KDM4E 958/4885ALDH1A1 1171/4885SMN1; SMN2 2629/4885 |
| US-20250289799-A1 | PYRIMIDINE COMPOUND, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL USE THEREOF | USP1, UPP1, UFL1 | KDM4E 1951/4885ALDH1A1 336/4885SMN1; SMN2 2646/4885 |
| US-20090253687-A1 | Fused Heterocyclic Compounds and Their Use as Mineralocorticoid Receptor Ligands | NR3C2, NR3C1, MC2R | KDM4E 3035/4885ALDH1A1 2708/4885SMN1; SMN2 4585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.